Meloxivet

RSS

meloxicam

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Meloxivet has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 18/06/2014

Authorisation details

Product details
Name
Meloxivet
Agency product number
EMEA/V/C/000124
Active substance
meloxicam
International non-proprietary name (INN) or common name
meloxicam
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AC06
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Eli Lilly and Company Limited 
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
14/11/2007
Contact address
Eli Lilly and Company Limited
Elanco Animal Health,
Lilly House
Priestley Road
Basingstoke
RG24 9NL
United Kingdom

Product information

28/05/2014 Meloxivet - EMEA/V/C/000124 - IG/0437

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Musculo-skeletal system

Therapeutic indication

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.

Assessment history

How useful was this page?

Add your rating